{
  "id": 6898147,
  "title": "Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial",
  "url": "https://urgent.news/2026/09/12/investigational-egfr-x-her3-therapy-supports-phase-iii-dose-after",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-12T09:20:10.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-egfr-her3-therapy-phase-iii.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase III IZABRIGHT-Lung01 registrational study.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Vietnam Investment Review",
        "title": "Kelun Biotech partner reports positive asthma Phase 2 trial results",
        "url": "https://urgent.news/2026/09/10/kelun-biotech-partner-reports-positive-asthma-phase-2-trial-results",
        "published": "2026-09-10T03:34:57.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}